Wang Qiong, Chen Sihui, Wang Junhui, Shang Huifang, Chen Xueping
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China.
Brain Sci. 2024 Sep 29;14(10):990. doi: 10.3390/brainsci14100990.
The landscape of pharmacological treatment for Alzheimer's disease (AD) has undergone significant transformations with the advent of disease-modifying therapies (DMTs) targeting β-Amyloid (Aβ) accumulation, one of the hallmark pathologies of AD. The approval and market introduction of monoclonal antibodies mark the dawn of a new era in AD therapeutics as well. Furthermore, considerable progress has also been made in the development of new drugs targeting non-Aβ and non-Tau protein pathways. These advancements are key in tackling the root causes of AD, offering hope for treatments that both relieve symptoms and slow disease progression, improving patient outcomes and quality of life. This review aims to provide a comprehensive update on the advances in drug development and application for AD, including those currently in clinical trials and those already approved for the market to treat patients.
随着针对β-淀粉样蛋白（Aβ）积聚的疾病修饰疗法（DMTs）的出现，阿尔茨海默病（AD）的药物治疗格局发生了重大变化，Aβ积聚是AD的标志性病理特征之一。单克隆抗体的获批和上市也标志着AD治疗新时代的到来。此外，在针对非Aβ和非Tau蛋白途径的新药开发方面也取得了相当大的进展。这些进展对于解决AD的根本原因至关重要，为既能缓解症状又能减缓疾病进展的治疗方法带来了希望，从而改善患者的治疗效果和生活质量。本综述旨在全面更新AD药物开发和应用的进展，包括目前正在进行临床试验的药物以及已获批上市用于治疗患者的药物。
